诺和诺德UBT251在华二期临床数据亮眼，减重效果近20%

Core Insights - Novo Nordisk's experimental weight loss drug UBT251 has shown significant weight reduction effects in its Phase II clinical trial in China, providing strong support for the company's search for new growth engines in the competitive weight loss market [1][3] - The drug demonstrated a maximum weight loss of 19.7% after 24 weeks of treatment, compared to an average weight loss of only 2% in patients receiving a placebo [1] - Despite the promising data, Novo Nordisk's stock has faced pressure in the capital markets, with a drop of over 60% in the past year, influenced by negative news regarding its next-generation weight loss drug Cagrisema and downgrades from multiple analysts [1][4] Clinical Trial Details - The Phase II trial involved 205 patients who were randomly assigned to receive doses of 2mg, 4mg, or 6mg of UBT251 or a placebo [3] - UBT251 is a triple agonist that simultaneously mimics three hormones involved in metabolism: GLP-1, GIP, and glucagon, suggesting it may have stronger efficacy compared to Novo Nordisk's current blockbuster weight loss drug Wegovy, which only targets GLP-1 [3] Investment and Market Strategy - The development of UBT251 represents a significant external investment for Novo Nordisk to maintain its leading position in the obesity market, with a $200 million upfront payment made for the rights to develop UBT251 outside of China [4] - The total value of this licensing deal could reach up to $2 billion as clinical progress continues and potential commercialization unfolds, which may boost investor confidence in Novo Nordisk's pipeline amid calls for strategic adjustments in response to recent R&D setbacks [4]